Search

TM5614

TM5614 is a novel, orally active, plasminogen activator inhibitor 1 (PAI-1) inhibitor[A228788,A228793,]. … PAI-1 is a marker of obesity, type 2 diabetes, and metabolic syndrome[L31673,A228793,A228798], and current studies are exploring downstream effects of its inhibition.

COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection

COVID-19 Spike-GM-CSF Protein Lactated Ringer's Injection is an intradermal injection currently being investigated in the clinical trial NCT03348670 (Discovery Stage (Proof-of-concept) COVID-19 Antigen

Prolectin-M

Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin. … [L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)).

Sodium copper chlorophyllin

This compound is used as a food colorant and supplement[A227718]. … SCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718

FINLAY-FR-1

FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373]. … , of the prophylactic FINLAY-FR-1 anti-SARS-CoV-2 Vaccine Candidate in a two-doses schedule.

Biomodulin T

Biomodulin T is a polypeptide fraction from bovine thymus with immunomodulatory effects.

Ropocamptide

Ropocamptide is a human cathelicidin that inhibits viral replication and while also playing a role in host defense against infection.

Benzoyloxymethylthiamine

Bifidobacterium bifidum

Lisocabtagene maraleucel

[A228493,L31588] Lisocabtagene maraleucel is a genetically modified autologous T-cell therapy that targets CD19, the B-lymphocyte surface antigen B4. … Lisocabtagene maraleucel is a chimeric antigen receptor (CAR) T-cell therapy, similar to [brexucabtagene autoleucel] and [axicabtagene ciloleucel].